Moderna launches Phase III COVE (Coronavirus Efficacy) trial of mRNA-1273 vaccine

The trial is expected to include about 30,000 participants in the U.S, evaluating 100 microgram doses of the vaccine against placebo. The primary endpoint will be prevention of symptomatic COVID-19 disease and key secondary endpoints include prevention of severe COVID-19,


Biospace Inc.